 CAMBRIDGE, Mass. and GOSSELIES, Belgium, Feb. 10, 2022 GLOBE NEWSWIRE -- iTeos Therapeutics, Inc. Nasdaq: ITOS, a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that Michel Detheux, PhD, President and Chief Executive Officer, will participate in two upcoming virtual investor conferences in February: 